ASH: Ferumoxytol Increases Hemoglobin, Iron Parameters, in Patients with Iron Deficiency Anemia
Patients with IDA with a history of unsatisfactory oral iron therapy appear to benefit from treatment with IV ferumoxytol.
ASH 2012
ASH: Patients with Mantle Cell Lymphoma Treated with Ibrutinib Have Durable Responses
The oral Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has an “unprecedented single agent overall response rate” in patients with relapsed or refractory mantle cell lymphoma (MCL), interim results of a global phase 2 study reported during the 54th American Society of Hematology Annual Meeting and Exposition.
ASH: First-Line Oral Proteasome Inhibitor MLN9708 Shows High Response Rates in Multiple Myeloma
The combination of the investigational weekly oral, proteasome inhibitor, MNL9708, plus standard dose lenalidomide and dexamethasone has antitumor activity at the recommended phase 2 dose in treatment-naïve patients with multiple myeloma, investigators reported at the 54th American Society of Hematology Annual Meeting and Exposition.
ASH: Asparaginase Erwinia Chrysanthemi ‘Well Tolerated’ Among Patients with ALL and L-ASP Allergy
Asparaginase Erwinia chrysanthemi (marketed as Erwinaze) is well tolerated among children and young adults diagnosed with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to the Escherichia coli-derived L-asparaginase (L-ASP), according to compassionate use protocol data presented during the 54th American Society of Hematology Annual Meeting and Exposition. L-ASP is part of standard chemotherapy regimens for ALL.
ASH: Aspirin Might Improve Survival in Refractory and Relapsed CLL
Adding aspirin therapy to FCR (fludarabine, cyclophosphamide and rituximab) improves outcomes for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to a single-institution study presented during the 54th American Society of Hematology Annual Meeting and Exposition.
ASH: PACE: Superior Molecular Response to Ponatinib in Chronic Myeloid Leukemia (CML)
Ponatinib treatment is associated with significant molecular response rates among patients intolerant to dasatinib and nilotinib or who have dasatimib- and nilotinib-resistant chronic myeloid leukemia (CML), according to an analysis of data from the open-label multinational phase 2 PACE clinical trial. The analysis was presented during the 54th American Society of Hematology Annual Meeting and Exposition.
ASH: Wide Variability Observed in Antifungal Use for Pediatric AML
Wide variability across U.S. children’s hospitals in antifungal use for pediatric acute myeloid leukemia (AML) does not appear to correlate with induction case fatality rates, according to a study presented during the 54th American Society of Hematology Annual Meeting and Exposition.
ASH: Higher Imatinib Exposures Associated with Better Chronic-Phase CML Outcomes
Among chronic myeloid leukemia (CML) patients, higher imatinib exposures were associated with better overall survival (OS) and event-free survival (EFS), according to an analysis of data from the WORLD CML Registry presented during the 54th American Society of Hematology Annual Meeting and Exposition.
ASH: Ponatinib Active in CML, Ph+ ALL Resistant to Dasatinib or Nilotinib
Ponatinib has substantial activity and is generally well tolerated in heavily pretreated patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation.
ASH: Quizartinib “Promising” for Relapsed, Refractory AML
Quizartinib is a promising treatment for refractory and relapsed acute myeloid leukemia (AML) after second-line chemotherapy or hematopoietic stem cell transplantation (HSCT), according to a cohort analysis of data from an open-label phase 2 safety and efficacy study presented during the 54th American Society of Hematology Annual Meeting and Exposition.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...